INCY Latest Press Releases

-- May 30, 2026 --

Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi/Minjuvi) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL Business Wire 8:00 AM

-- May 26, 2026 --

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire 8:00 AM

-- May 20, 2026 --

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery Business Wire 8:00 AM

-- May 19, 2026 --

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development Business Wire 8:00 AM

-- May 12, 2026 --

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress Business Wire 9:30 AM

-- May 7, 2026 --

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis Business Wire 8:50 AM

-- May 6, 2026 --

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- May 3, 2026 --

New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1] PRNewswire 12:01 PM

New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1] PRNewswire 12:00 PM

-- May 1, 2026 --

Incyte Announces FDA Approval of Jakafi XR (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease Business Wire 5:28 PM

-- April 29, 2026 --

Incyte to Present at Upcoming Investor Conferences Business Wire 8:00 AM

-- April 28, 2026 --

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates Business Wire 7:00 AM

Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer Business Wire 7:00 AM

-- April 23, 2026 --

MINJUVI (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia PRNewswire 3:00 AM

-- April 21, 2026 --

Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire 10:00 AM

-- April 9, 2026 --

Incyte to Report First Quarter Financial Results Business Wire 8:00 AM

-- April 7, 2026 --

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales Globe Newswire 7:30 AM

-- April 2, 2026 --

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) Globe Newswire 7:01 AM

-- March 28, 2026 --

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting Business Wire 3:00 PM

-- March 25, 2026 --

Incyte Announces Executive Leadership Appointments Business Wire 9:00 AM

-- March 20, 2026 --

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting Business Wire 10:00 AM

-- March 17, 2026 --

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI (tafasitamab) for Follicular Lymphoma in Argentina and Mexico Globe Newswire 7:30 AM

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI (tafasitamab) in Brazil Globe Newswire 7:30 AM

-- March 6, 2026 --

Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) Business Wire 4:42 PM

-- March 2, 2026 --

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 27, 2026 --

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata PRNewswire 8:12 AM

-- February 19, 2026 --

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Ra, and Others | DelveInsight PRNewswire 5:31 PM

-- February 17, 2026 --

Registration Momentum Builds Across the Oncology Pipeline Globe Newswire 10:48 AM

Incyte to Present at Upcoming Investor Conferences Business Wire 8:00 AM

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

-- February 10, 2026 --

Incyte Reports Fourth Quarter and Full Year 2025 Financial Results Business Wire 7:00 AM

-- January 30, 2026 --

Incyte Announces Positive CHMP Opinion for Zynyz (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) Business Wire 9:29 AM

-- January 27, 2026 --

Incyte to Report Fourth Quarter and Year-End 2025 Financial Results Business Wire 8:00 AM

-- January 5, 2026 --

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as a First-line Treatment for Diffuse Large B-Cell Lymphoma Business Wire 7:30 AM